SEC Form 10-Q filed by CVS Health Corporation
$CVS
Retail-Drug Stores and Proprietary Stores
Consumer Staples
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays |
| 10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen |
| 5/30/2024 | $61.00 | Neutral | Robert W. Baird |
| 5/7/2024 | $99.00 → $59.00 | Buy → Hold | TD Cowen |
| 5/2/2024 | $85.00 → $60.00 | Buy → Neutral | UBS |
| 5/1/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 5/1/2024 | $87.00 → $60.00 | Outperform → Market Perform | Leerink Partners |
| 3/6/2024 | $78.00 | Equal Weight | Barclays |
Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior yearThird quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segmentGenerated year-to-date cash flow from operations of $7.2 billionCEO Commentary "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Serv
Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today. As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pha
Roger Farah Named Executive Chairman of the Board Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10 WOONSOCKET, R.I., Oct. 18, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced that David Joyner was appointed President and Chief Executive Officer, effective October 17, replacing Karen Lynch, who stepped down from her position in agreement with the company's Board of Directors. Joyner also joined the Board of Directors. In addition, current Chairman of the Board, Roger Farah, will now be Executive Chairman.
Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today. As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pha
Roger Farah Named Executive Chairman of the Board Company provides preliminary guidance for third quarter 2024 GAAP diluted Earnings per Share (EPS) of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10 WOONSOCKET, R.I., Oct. 18, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced that David Joyner was appointed President and Chief Executive Officer, effective October 17, replacing Karen Lynch, who stepped down from her position in agreement with the company's Board of Directors. Joyner also joined the Board of Directors. In addition, current Chairman of the Board, Roger Farah, will now be Executive Chairman.
WOONSOCKET, R.I., Aug. 14, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Heidi Capozzi will join the company as Executive Vice President, Chief People Officer, effective September 9. She will lead the human resources, labor relations, compensation and benefits, and corporate social responsibility teams who support CVS Health's strategy to build a world of health around every consumer. "Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and adv
Barclays upgraded CVS Health from Equal Weight to Overweight and set a new price target of $82.00 from $63.00 previously
TD Cowen upgraded CVS Health from Hold to Buy and set a new price target of $85.00 from $59.00 previously
Robert W. Baird initiated coverage of CVS Health with a rating of Neutral and set a new price target of $61.00
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
3 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior yearThird quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segmentGenerated year-to-date cash flow from operations of $7.2 billionCEO Commentary "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Serv
WOONSOCKET, R.I., Oct. 7, 2024 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, November 6th, 2024, at 8:00 a.m. ET to discuss third quarter 2024 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — includi
WOONSOCKET, R.I., Sept. 19, 2024 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 1, 2024, to holders of record on October 21, 2024. About CVS HealthCVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support i
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
10-Q - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:CVS) revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $374,736, and 7 were calls, valued at $388,184. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $53.0 to $77.5 for CVS Health over the last 3 months. Analyzing Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metr
Across the recent three months, 15 analysts have shared their insights on CVS Health (NYSE:CVS), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 9 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 2 0 0 3M Ago 5 0 6 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.13, along with a high estimate of $86.00 and a low estimate of $58.00. Observing
Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Neutral and maintains $58 price target.